Zoetis (NYSE:ZTS) Stock Rating Lowered by Bank of America

Zoetis (NYSE:ZTS) was downgraded by Bank of America from a “buy” rating to a “neutral” rating in a note issued to investors on Monday. They presently have a $135.00 target price on the stock. Bank of America‘s price target would indicate a potential upside of 11.69% from the stock’s current price.

ZTS has been the topic of several other research reports. HSBC set a $140.00 price target on Zoetis in a report on Wednesday. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research report on Monday. Stifel Nicolaus reduced their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. UBS Group cut their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and an average price target of $161.55.

Zoetis Price Performance

Shares of NYSE:ZTS traded up $2.21 during midday trading on Monday, reaching $120.87. 1,339,289 shares of the company were exchanged, compared to its average volume of 3,305,059. The stock has a market cap of $53.27 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 2.46 and a beta of 0.97. The business’s fifty day moving average is $130.95 and its two-hundred day moving average is $145.94. Zoetis has a one year low of $115.25 and a one year high of $179.29. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the company posted $1.58 EPS. The company’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts predict that Zoetis will post 6.07 earnings per share for the current year.

Institutional Trading of Zoetis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nova Wealth Management Inc. bought a new stake in Zoetis during the first quarter valued at about $25,000. Halbert Hargrove Global Advisors LLC raised its holdings in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. 1248 Management LLC bought a new position in Zoetis in the first quarter worth about $27,000. Saudi Central Bank purchased a new stake in shares of Zoetis during the first quarter valued at about $29,000. Finally, REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.